

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to "Commissioner for Patents, Washington, D.C. 20231" on

1644  
Attorney Docket No. 9950-0002

November 27, 2002  
11/27/02 Signature Margaret K. Sundige

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent & Trademark Office  
O P E JC18 REC 03/2002  
Application of:  
ULRICH et al.

U.S. Serial No.: 09/402,273

Group Art Unit: 1644

U.S. Filing Date: December 13, 1999

Examiner: P. Huynh

International Application No.: PCT/EP98/02138

International Filing Date: 03 April 1998

Title: ALLERGEN FORMULATION

RECEIVED  
DEC 05 2002  
TECH CENTER 1600/2900

AMENDMENT TRANSMITTAL LETTER

Commissioner for Patents  
Washington, DC 20231

Sir:


Transmitted herewith for filing is an amendment in the above patent application in response to the Office Action of August 27, 2002.

- Also enclosed: Declaration under 37 CFR § 1.132.  
 No additional Amendment Fee is required.

No. of Claims After Amendment		Most Claims Previously Paid		Extra Claims				Additional Fee	
A. Total Claims	14	-	12	=	2	x	\$18	=	0.00
B. Ind. Claims	1	-	1	=	0	x	\$84	=	0.00
C. If amended to contain multiple dependent claims, add \$280					\$280	=			0.00
D. Total Amendment Fee (Total of A, B & C)								=	0.00
E. If small entity, 50% reduction of Total Amendment Fee (50% of D)								=	0.00
F. Total Amendment Fee (D minus E)								=	0.00

The Commissioner is hereby authorized to charge any fees under 37 CFR §§ 1.16, 1.17 and 1.21 which may be required by this paper, or to credit any overpayment, to Deposit Account No. 18-0580. A duplicate copy of this sheet is enclosed.

By:

Respectfully submitted,  
  
Louis L. Wu  
Registration No. 44,413

REED & ASSOCIATES  
800 Menlo Avenue, Suite 210  
Menlo Park, California 94025  
(650) 330-0900 Telephone  
(650) 330-0980 Facsimile

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to "Commissioner for Patents, Washington, D.C. 20231" on

Attorney Docket No. 9950-0002

November 27, 2002

11/27/02 Signature Margaret K. Sunridge

#  
14

RECEIVED

DEC 05 2002

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:  
ULRICH et al.

U.S. Serial No.: 09/402,273

Group Art Unit: 1644

U.S. Filing Date: December 13, 1999

Examiner: P. Huynh

International Application No.: PCT/EP98/02138

International Filing Date: 03 April 1998

Title: ALLERGEN FORMULATION

AMENDMENT UNDER 37 CFR § 1.111

Commissioner for Patents  
Washington, DC 20231

Sir:

This is in response to the Office Action in the above-identified case, mailed on August 27, 2002. Accompanying this paper, applicants have submitted the Declaration of Derek Richardson pursuant to 37 CFR §1.132. Reconsideration of the application in view of the Declaration and following remarks and amendments is respectfully requested.

AMENDMENTS

IN THE CLAIMS: / / /

Please amend claims 1, 2, and 6-8 as indicated in Appendix A. The amended claims read as follows:

1. A pharmaceutical composition capable of selectively enhancing a TH<sub>1</sub> response over a TH<sub>2</sub> response, comprising tyrosine, an allergen or allergen extract, and 3-DMPL.
2. A composition according to claim 1, wherein the allergen or allergen extract is coated with and/or adsorbed onto tyrosine.